AbbVie Earnings Reports

AbbVie reported a 5.6% increase in net revenues for Q4 2024, reaching $15.102 billion. The company's adjusted diluted EPS was $2.16, which includes an unfavorable impact of $0.88 related to acquired IPR&D and milestones expense. While some portfolios like Neuroscience and Oncology experienced growth, others like Aesthetics saw a decrease. The company provides 2025 adjusted diluted EPS guidance range of $12.12 to $12.32.

AbbVie reported a 3.8% increase in net revenues for the third quarter of 2024, reaching $14.460 billion. The company's adjusted diluted EPS was $3.00, a 1.7% increase. AbbVie also raised its full-year adjusted diluted EPS guidance and announced a dividend increase.

AbbVie reported a strong second quarter with net revenues of $14.462 billion, a 4.3% increase, and a GAAP EPS of $0.77. The company is raising its full-year adjusted diluted EPS guidance to $10.71 - $10.91.

AbbVie reported a 0.7% increase in net revenues to $12.310 billion for Q1 2024. GAAP diluted EPS was $0.77, while adjusted diluted EPS was $2.31, a decrease of 6.1 percent. The company has raised its full-year adjusted diluted EPS guidance.

AbbVie reported a decrease in net revenues and diluted EPS for the fourth quarter of 2023. Worldwide net revenues were $14.301 billion, a decrease of 5.4 percent. Diluted EPS was $0.46 on a GAAP basis, a decrease of 66.7 percent, while adjusted diluted EPS was $2.79, a decrease of 22.5 percent.

AbbVie reported Q3 2023 net revenues of $13.927 billion, a decrease of 6.0 percent. The company's adjusted diluted EPS was $2.95. AbbVie raised its full-year 2023 adjusted diluted EPS guidance and its floor EPS outlook for next year and increased its quarterly dividend.